Regeneron Pharmaceuticals (NASDAQ:REGN) is a biotech company focused on discovering, developing, and commercializing medicines for serious diseases. Armed with a robust research and development engine, Regeneron tackles a range of medical challenges, from rare diseases to cancer and infectious diseases. The company is known for its comprehensive pipeline of potential therapies and has launched several successful drugs that address significant unmet medical needs. Objectives for Regeneron primarily include pushing the boundaries of science to bring innovative treatments to patients, continuing its growth in the biopharmaceutical sector, and expanding its global footprint to ensure broader access to its life-changing medications.